Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
12,662,672
-
Share change
-
+12,662,672
-
Total reported value
-
$269,884,064
-
Price per share
-
$21.99
-
Number of holders
-
59
-
Value change
-
+$269,884,063
-
Number of buys
-
59
Institutional Holders of JOUNCE THERAPEUTICS INC - COM (JNCE) as of Q1 2017
As of 31 Mar 2017,
JOUNCE THERAPEUTICS INC - COM (JNCE) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,662,672 shares.
The largest 10 holders included
FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, Redmile Group, LLC, Pharmstandard International S.A., Omega Fund Management, LLC, Partner Fund Management, L.P., DEERFIELD MANAGEMENT CO, Cormorant Asset Management, LLC, Artal Group S.A., and MILLENNIUM MANAGEMENT LLC.
This page lists
59
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.